4 DCRI Faculty Among Clarivate’s Most Highly Cited Scientists
Researchers from the Duke Clinical Research Institute (DCRI) were once again named to Clarivate's Most Highly Cited Scientists list.
DCRI to Partner with Novo Nordisk on Large-Scale Global Cardiovascular Study in Acute Myocardial Infarction
By randomizing 10,000 adult patients, ARTEMIS will evaluate the effects of a study medicine versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.
Antibiotic Shows Effectiveness Against Deadly Staph Infections
An antibiotic that has shown effectiveness for bacterial pneumonia also appears successful in fighting methicillin-resistant staph infections, reports a team led by Duke Health.
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO)
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
(IPF/ILD-PRO)
Hispanic Heritage and Language Influence COVID-19 Testing and Vaccination
When it comes to COVID-19 testing and vaccination, not all Hispanic populations respond the same.
The Doctor Who Wants to Change How We Treat Cardiovascular Disease
Sept. 28, 2023 — Cardiovascular disease is the number one killer of people in the United States and worldwide.
ACTIV-6 trials show no benefit to fluticasone furoate for COVID-19 symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no clinical benefit to taking fluticasone furoate for treatment of mild-to-moderate COVID-19 symptoms.
CardioHealth Alliance Study Aims to Assess How to Improve Cholesterol Management in Patients with ASCVD
CardioHealth Alliance is announcing a new project sponsored by Amgen aimed at assessing and gathering data regarding how to improve quality of care among patients hospitalized for ASCVD. This work, referred to as the “Test to Treat” project, will be led by cardiovascular disease prevention specialist and DCRI faculty member Neha Pagidipati, MD, MPH.
Study Confirms No Benefit to Taking Fluvoxamine for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine at a dosage of 100 mg twice daily for 13 days for the treatment of mild-to-moderate COVID-19 symptoms.
STAR Students Complete Ninth-Annual Research Training Program
A group of promising young scientists completed the ninth annual Duke STAR Program in August, after spending the summer building research skills and working side-by-side with Duke University faculty to research medications and how they are being used.